Why Tilray Stock Dropped This Week, Even After President Trump's Executive Order
Key Points
Investors felt the cannabis executive order didn't go far enough.
Tilray's CEO backed President Trump's decision, but called it an "incremental step."
- 10 stocks we like better than Tilray Brands ›
It was an exciting week in the cannabis sector. Rumors that President Trump was planning to reclassify marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA) had pot stock shares soaring.
The stock of global cannabis company Tilray Brands (NASDAQ: TLRY) was up 28% at its high this week. However, even after the president did, in fact, sign an executive order, Tilray shares lost all of that gain. As of midday on Friday, Tilray stock was actually down 7.4% for the week, according to data provided by S&P Global Market Intelligence.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Image source: Getty Images.
Long path to legalization
The executive order mainly focused on improving access to medical marijuana and cannabidiol (CBD) products for conditions like pain, anorexia, and the side effects induced by chemotherapy. Medical marijuana access will help expand Tilray's business, but not as much as loosening regulations on recreational marijuana would have.
Tilray immediately issued a press release saying that it will accelerate the advancement of its U.S. medical cannabis operations. CEO Irwin Simon put out this statement:
We support President Trump's decision to reschedule cannabis as a constructive and necessary evolution of U.S. federal policy. This action aligns regulation with a vast body of scientific and medical data supporting cannabis medical use and safety, economic progress, and a healthcare-focused framework, while creating a more credible foundation for medical cannabis research, clinical development, and regulatory clarity.
He also effectively called the order an incremental step toward legalization.
That's the problem for investors. An incremental step won't move the needle for Tilray's business anytime soon. While the new policies will benefit Tilray and other cannabis companies, investors had hoped for a more significant boost to the business.
Should you buy stock in Tilray Brands right now?
Before you buy stock in Tilray Brands, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Tilray Brands wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $506,935!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,067,514!*
Now, it’s worth noting Stock Advisor’s total average return is 958% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of December 19, 2025.
Howard Smith has positions in Tilray Brands. The Motley Fool recommends Tilray Brands. The Motley Fool has a disclosure policy.
Recommended Articles
